ReviewCurrent rheumatology reports2019
Immune Checkpoint Inhibitor-Induced Myositis: a Case Report and Literature Review.
Review in Current rheumatology reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 3 syntheses or guidelines pooled it, 55 citations in OpenAlex.
- Immune Checkpoint Inhibitor-Induced Myocarditis with Myositis/Myasthenia Gravis Overlap Syndrome: A Systematic Review of Cases.The oncologist · 2021Pooled it
- Incidence and Distinct Features of Immune Checkpoint Inhibitor-Related Myositis From Idiopathic Inflammatory Myositis: A Single-Center Experience With Systematic Literature Review and Meta-Analysis.Frontiers in immunology · 2021Pooled it
- Management of immune checkpoint inhibitor-related rheumatic adverse events.Thoracic cancer · 2020Pooled it
- Article
- Use of Immunoglobulin Replacement Therapy in Clinical Practice: A Review.Journal of immunotherapy and precision oncology · 2025Review
- A case report of immune checkpoint inhibitor-related myositis and cholangitis induced by pembrolizumab.Clinical case reports · 2024Article
- The Role of Environmental Factors in the Development of Idiopathic Inflammatory Myopathies: a Narrative Review.Current rheumatology reports · 2023Review
- Article
- Immune interactions in pembrolizumab (PD-1 inhibitor) cancer therapy and cardiovascular complications.American journal of physiology. Heart and circulatory physiology · 2023Review
- Immune-Related Uncommon Adverse Events in Patients with Cancer Treated with Immunotherapy.Diagnostics (Basel, Switzerland) · 2022Review
- Immune-checkpoint inhibitors: long-term implications of toxicity.Nature reviews. Clinical oncology · 2022Review
- Neurological disorders associated with immune checkpoint inhibitors: an association with autoantibodies.Cancer immunology, immunotherapy : CII · 2022Review
- Neurologic Toxicity of Immune Checkpoint Inhibitors: A Review of Literature.Frontiers in pharmacology · 2022Review
- Acetylcholine receptor binding antibody-associated myasthenia gravis, myocarditis, and rhabdomyolysis induced by tislelizumab in a patient with colon cancer: A case report and literature review.Frontiers in oncology · 2022Article
- Atezolizumab-associated Dermatomyositis in Advanced Small-cell Lung Carcinoma.Internal medicine (Tokyo, Japan) · 2021Article
- Tumor Immune Microenvironment and Immunosuppressive Therapy in Hepatocellular Carcinoma: A Review.International journal of molecular sciences · 2021Review
- A Rare Case of Pembrolizumab-Induced Dermatomyositis in a Patient with Cancer of Unknown Primary Origin.The American journal of case reports · 2021Article
- Immune Checkpoint Inhibitors and Neurotoxicity.Current neuropharmacology · 2021Review
- Association between incidental statin use and skeletal myopathies in patients treated with immune checkpoint inhibitors.Immunotherapy advances · 2021Article
- Myositis induced by durvalumab in a patient with non-small cell lung cancer: A case report.Thoracic cancer · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose of the reviewWe clarify clinical characteristics of patients with immune checkpoint inhibitor (ICI)-induced myositis. RECENT
findingsIn 13 of 15 cases with ICI-induced myositis, the type of malignancy was melanoma. Eight, 4, and 3 patients received anti-PD-1 alone, anti-CTLA4 alone, and a combination of those, respectively. The mean period to the onset of ICI-induced myositis from the initiation of ICI was 4 weeks. Myocarditis was a complication in five patients. Seven of the patients died. The causes of death were myocarditis in three patients, respiratory muscle paralysis in two patients, and cancer progression in two patients. In patients without myocarditis or respiratory muscle paralysis, the prognosis for myositis was favorable with normalization of the CK levels occurring upon the cessation of ICI and the administration of immunosuppressive agents. Myocarditis and respiratory muscle paralysis are the major causes of death as immune-related adverse events in patients with ICI-induced myositis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.